Description

Independent Life Sciences executive and former Partner at EY-Parthenon with 15+ years of experience spanning top-tier strategy consulting and global biopharma leadership. Most recently, served as Global Head of Pricing & Market Access and Director of Business Development & Licensing (BD&L) for CSL Vifor’s $500M-$1B Orphan Diseases franchise. Prior to this, I led the Global Value Strategy for a $3B Immunology portfolio at Shire. Holding a PhD in Virology, I bridge clinical science with commercial viability. I specialize in advising biopharma clients on market access strategy, pricing, commercial due diligence (CDD), asset valuation, launch readiness, and complex global payer negotiations. My track record includes directing pricing strategies that supported over $1B in biotech acquisitions and leading the market access strategy for three global pharmaceutical launches across rare diseases, immunology, and oncology.

Industry field of expertise

Languages

English
Native or bilingual

Workplace preferences

Can work on-site

London (up to 50km)

INDEPENDENT LIFE
Advisor
PHARMACEUTICALS INDUSTRY
January 2026 - Today (5 months)
London, UK
• • Fractional Executive Leadership & Interim Management: Providing immediate, "plug-and-play" senior leadership (e.g., Interim VP of Market Access / Fractional Chief Commercial Officer) to biopharma companies to ensure strategic continuity during critical hiring gaps and continual market access strategy development.
• • Commercial Due Diligence (CDD) & Asset Valuation: Partnering with Private Equity, Venture Capital, and biopharma BD&L teams to deliver rapid, rigorous asset valuations—assessing market access viability, pricing potential, and peak revenue to de-risk high-stakes M&A and licensing transactions.
• • Global Pricing Governance & Launch Readiness: Architecting end-to-end market access strategies and
compelling payer value propositions to seamlessly transition specialized assets (Orphan/Rare, Immunology, Oncology) from Phase II/III clinical trials to successful commercial launch.
Pricing strategy Market Access Reimbursement Life Sciences Commercial strategy
EY-PARTHENON,
Partner – Commercial & Market Access Service Lines Lead
PHARMACEUTICALS INDUSTRY
January 2023 - January 2026 (3 years)
London, UK
• • Market Access Practice Leadership: Directed a team of 20+ specialists, acting as the senior strategic advisor to mid- and large-cap biopharma C-suites on complex global launch, pricing, and mandates.
• • Asset Commercialization & Risk Mitigation: Spearheaded comprehensive global pricing strategies, P&R risk assessments, and go-to-market plans, directly maximizing peak revenue potential for highly specialized clinical assets.
• • Responsible for comprehensive global pricing strategy, risk assessments, supporting client go-to-market plans, and driving revenue maximization globally.
• • Key
Market Access Pricing strategy Commercial strategy Life Sciences Reimbursement
CSL VIFOR,
Global Head of Pricing & Market Access – Orphan
PHARMACEUTICALS INDUSTRY
January 2021 - January 2023 (2 years)
Zürich, Switzerland
• • Oversaw market access strategy and implementation for the largest portfolio in the company ($500M) – the orphan disease franchise – while holding a dual role as Senior Director of Business Development & Licensing.
• • Worked across stakeholders (medical, marketing, regulatory, clinical) to create compelling value propositions and competitive access strategies for rare disease products.
• • Implemented new internal corporate processes and pricing governance to better align the company to industry standards; established a toolkit with a standardized set of deliverables to achieve low variability across markets.
• • Explored alternative pathways for early payer engagement, such as the Mechanism for Orphan Coordinated Access (MoCA), creating education opportunities to preempt key questions and streamline formal HTA assessments.
Pricing strategy Market Access Reimbursement Life Sciences Commercial strategy